Aims To determine the effects of hepatic cirrhosis on the pharmacodynamics and pharmacokinetics of rocuronium bromide. Methods We studied 21 healthy patients and 17 patients with mild or moderate cirrhosis (Child-Pugh Class A and B). Patients were premedicated with diazepam orally; anaesthesia was induced with fentanyl and thiopentone, and maintained with isoflurane 0.6% (end-tidal) and nitrous oxide 66% in oxygen. The compound action potential of the adductor pollicis muscle in response to supramaximal stimulation of the ulnar nerve was recorded using the train-of-four (TOF) twitch technique. A bolus dose of rocuronium 0.6 mg kg −1 was then given. Venous blood samples were taken for up to 8 h, and plasma rocuronium concentrations determined by h.p. Keywords: hepatic cirrhosis, neuromuscular block, rocuronium (Child's class B), and eight healthy patients, Khalil and Introduction colleagues [6] found that the onset of neuromuscular block was slower in cirrhotic than in healthy patients (158 s vs Rocuronium bromide is an aminosteroid non-depolarizing neuromuscular blocking agent with a more rapid onset of 108 s), and that recovery of twitch height (T 1 5T 0 ) to 75% and 90% was prolonged. The plasma concentrations of action than other currently available non-depolarizing drugs, but a duration of action comparable with vecuronium [1] .
Introduction colleagues [6] found that the onset of neuromuscular block was slower in cirrhotic than in healthy patients (158 s vs Rocuronium bromide is an aminosteroid non-depolarizing neuromuscular blocking agent with a more rapid onset of 108 s), and that recovery of twitch height (T 1 5T 0 ) to 75% and 90% was prolonged. The plasma concentrations of action than other currently available non-depolarizing drugs, but a duration of action comparable with vecuronium [1] .
rocuronium were more variable in the cirrhotic patients, and pharmacokinetic analysis showed that the central volume The other aminosteroid non-depolarizing neuromuscular blocking drugs, pancuronium and vecuronium, have been of distribution and mean residence time were greater in the cirrhotic. Although the mean clearance was lower in the shown to have a prolonged effect and an increased elimination half-life in hepatic cirrhosis [2, 3] . Rocuronium, cirrhotic group (2.41 vs 2.79 ml kg −1 min −1 ), this did not achieve statistical significance. More recently, Magorian and like vecuronium, is a monoquaternary cation and might be expected to undergo considerable biliary excretion [4] , and colleagues studied a group of 10 patients with liver dysfunction of diverse aetiology and compared them with this has been directly suggested by work in the cat [5] .
There have been two previous studies of the pharmaco-10 healthy patients studied previously [7] . They found no difference in either time to onset of block or recovery of dynamics and pharmacokinetics of rocuronium in cirrhosis, with conflicting findings. In a study of 10 cirrhotic patients twitch height (T 1 5T 0 ) to 25% (clinical duration). They applied a population approach to pharmacokinetic analysis, and found an increase in initial volume of distribution (V 1 ), V 3 ) in the patients with liver dysfunction. They failed to Blood samples find a significant difference in clearance between the groups, but the elimination half-life was increased in the patients A venous sampling cannula was inserted in the antecubital fossa of the arm used for neuromuscular monitoring. Blood with liver dysfunction, from 76 to 111 min.
We undertook this study to help resolve the effects of samples (4 ml) were taken prior to and at 1, 2, 4, 7, 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240, 300, 360, 420 and hepatic cirrhosis on the pharmacodynamics and pharmacokinetics of rocuronium bromide, using a larger number of 480 min following administration of rocuronium. The samples were anti-coagulated with lithium heparin, and patients than in previous studies, and a more prolonged sampling regime.
immediately centrifuged. Plasma (2 ml) was mixed with 1 m sodium dihydrogen phosphate (0.5 ml) and then cooled in ice and deep frozen within 30 min of collection. Rocuronium Methods analysis was performed using high pressure liquid chromatography, followed by post-column ion-pair extraction and The study received Hospital Ethics Committee approval and fluorometric detection [10] . Samples were analysed for a CSM Clinical Trial Exemption Certificate. We recruited rocuronium and its potential derivatives, 17-hydroxy rocu-38 patients, who gave their written informed consent.
ronium and desallyl rocuronium. The assay had a coefficient Twenty-one of the patients, undergoing elective surgery, of variation, for rocuronium, of 8% over the range were healthy (ASA class 1 or 2), and had no clinical history 10-20 000 ng ml
; for 17-hydroxy rocuronium it was 7%, or biochemical evidence of renal or hepatic impairment.
over the range 20-20 000 ng ml −1 . Seventeen patients, who were undergoing injection sclerotherapy of oesophageal varices, had hepatic cirrhosis of mild to moderate severity (Child-Pugh class A and B) [8] . They Pharmacokinetic analysis had a history of chronic liver disease and portal hypertension Mean plasma rocuronium concentrations for the healthy and of intra-hepatic origin. The cirrhosis had been confirmed cirrhotic groups were calculated at each sampling time. by liver biopsy, ultrasound, or radio-nuclide scan.
Further analysis was performed by fitting a compartmental Exclusion criteria included any neuromuscular disorder, model to the data of each patient by non-linear regression, or treatment with drugs known to prolong the action of using the NONMEM programme [11] . Two and three neuromuscular blocking agents (e.g. aminoglycoside anticompartment models were fitted. The model adopted in biotics), or to interfere with the rocuronium assay (e.g. each patient was determined by examination of plots of metronidazole). A full blood count, clotting studies and predicted vs. measured plasma concentrations, and the biochemical profile were estimated in all patients within NONMEM objective function (the log likelihood of the 24 h prior to the operation. data conditional upon the fitted model). The compartment models were specified in terms of clearance, the compartment volumes V 1 , V 2 , V 3 , and the interAnaesthesia compartmental clearances Q 1 and Q 2 , where: All the patients were premedicated with diazepam 5-10 mg orally. Anaesthesia was induced with fentanyl 1 mg kg −1 Q 1 =V 1 k 12 =V 2 k 21 , and Q 2 =V 1 k 13 =V 3 k 31 followed by thiopentone 3-5 mg kg −1 intravenously and
The elimination half-life was obtained from the fitted maintained with isoflurane (0.6% end-tidal) in nitrous oxide parameters by standard formulae. 66% in oxygen.
The pharmacodynamic model incorporated an additional effect compartment of negligible volume, in which the temporal profile of drug concentration was determined by Monitoring the rate constant for drug exit from the compartment k eo The end-tidal concentration of isoflurane was monitored [12] . The effect was modelled using the Hill equation, with continuously using infra-red absorption ('Capnomac', the effect related to the plasma concentration (Cp ss ) which Datex), and stabilised for 15 min. During this period, would, at steady state, produce the observed effect: electromyographic (EMG) neuromuscular monitoring was begun using the Medelec MS6 four (TOF) stimuli were applied to the ulnar nerve at the wrist every 12.5 s and the surface compound muscle action potential of the adductor pollicis was recorded. The arm where: Cp ss 50 is the plasma concentration which would, at steady was wrapped in cotton wool to maintain the skin temperature above 32.5°C, as measured by a surface probe.
state, produce 50% depression of the electromyographic response. When the baseline EMG recordings were stable, rocuronium 0.6 mg kg −1 was given as a bolus dose into a fastc is the slope of the concentration-response curve. The pharmacokinetic and pharmacodynamic models were flowing intravenous infusion, in the arm opposite to that used for neuromuscular monitoring. This dose is twice the fitted sequentially. Thus the fitted pharmacokinetic parameters are conditional only upon the measured plasma ED 95 of rocuronium [1] . Tracheal intubation was performed within 2 min of administration of rocuronium. EMG concentration data; the pharmacodynamic parameters reflect the measured electromyographic depression and the fitted monitoring was continued until the TOF ratio (T 4 5T 1 ) was greater than 70%. No anticholinesterase was used.
pharmacokinetic model.
The mean recovery times were prolonged in the cirrhotic Statistical analysis group compared with the healthy group. The prolongation of 25% recovery of T 1 5T 0 (clinical duration), 50% recovery Comparison of plasma rocuronium concentrations, the recovery times, and the derived pharmacokinetic and T 1 5T 0 and 75% recovery T 1 5T 0 was statistically significant (P<0.05). The time to recovery of the train-of-four ratio pharmacodynamic parameters between healthy and cirrhotic patients, was performed using Student's t-test. A value of (T 4 5T 1 ) to 70% was increased by 50% in the cirrhotic group (P<0.01). P<0.05 was taken to indicate a statistically significant difference.
Pharmacokinetics

Results
Mean plasma rocuronium concentrations in the two groups The two groups were comparable for age, weight and height are plotted in Figure 1 . There was an initial rapid fall in (Table 1 ). There was a higher proportion of females in the plasma rocuronium concentration, which was similar in cirrhotic group. Of the cirrhotics, 10 were Child-Pugh both groups. After 10 min, the plasma concentrations fell class A, and 7 were Child-Pugh class B (Table 2) . more slowly in the cirrhotic group. The plasma concentrations were significantly higher in the cirrhotic group from 20 to 300 min compared with those in the healthy group.
Pharmacodynamics
Closer examination of the levels over the first 60 min The mean time to 90% depression of the first response of (Figure 1 inset) showed that the plasma rocuronium concenthe train of four was 63.6 s in the healthy group, and 60.3 s tration was slightly lower in the cirrhotic group at 1, 2 and in the cirrhotic group (not significant). Nor was there any 4 min, but this difference was not statistically significant. significant difference between the groups in the maximum
The mean peak plasma concentration of 17-block achieved (Table 3) .
hydroxyrocuronium at 1 min was 112 ng ml −1 (range 53-174 ng ml −1 ) in healthy patients, and was 108 ng ml
(range 52-193 ng ml −1 ) in cirrhotic patients. 17- the two groups in Table 4 . The most salient difference between the groups is that plasma clearance was significantly Discussion reduced in the cirrhotic group (2.66 vs 3.70 ml kg −1 min −1 ;
P<0.005).
The fast redistribution half-life (t D p ) is comparTwo previous studies of the pharmacokinetics and pharmacodynamics of rocuronium in hepatic cirrhosis contain several able between the groups, but the slow redistribution halflife (t D
) and the elimination half-life (t D ,z ) were both discrepant findings [6, 7] ; the present attempt to clarify the picture has the advantage of a larger sample size, and more significantly longer in the cirrhotic group compared with the healthy group. frequent and prolonged sampling than previous studies, in one of which a comparison was made with historical The volume of the rapidly equilibrating peripheral compartment, V 2 , was increased in the cirrhotic group; the controls [7] . Our patients were not so severely affected as those studied previously. The majority of our cirrhotic total volume of distribution, V ss , was not significantly increased in the cirrhotic group.
patients were in Child-Pugh class A, whereas those studied by Khalil and others were all in Child class B [6] , and The exit rate constant for the effect compartment k eo was significantly increased in the cirrhotic group; the parameters Magorian and others studied severely affected patients, with eight patients in Child class C [7] . of the concentration-effect curve, Cp ss 50 and c, were very similar in the two groups.
The most striking pharmacodynamic finding of the present study is the prolongation of neuromuscular block in and Magorian found the volume of all three model compartments to be increased in patients with liver cirrhotic patients given rocuronium compared with healthy patients. Recovery of T 1 5T 0 to 25%, 50% and 75%, and dysfunction [5] . As patients in both these studies had more severe liver disease, they are more likely to have suffered recovery of T 4 5T 1 to 70% were all significantly prolonged in the cirrhotic group; the prolongation of the recovery with significant ascites, and thus have increased extracellular fluid volume, which may account for the increase. index from 26 to 38.2 min in the cirrhotic group did not quite reach statistical significance. These findings show a Previous studies of other non-depolarizing neuromuscular blocking agents in cirrhosis have demonstrated increases in more clear cut effect of cirrhosis than previous work, with which they are however broadly consistent. Thus Khalil and the volume of distribution of pancuronium [2] , fazadinium
PK-PD of rocuronium in cirrhosis
[15] and atracurium [16] , though the volume of distribution colleagues also showed prolongation of recovery of T 1 5T 0 to 75%, and a doubling of the recovery index in cirrhosis from of vecuronium has been found to be unchanged [3, 17] . The increase in volume of distribution of the older 17 to 35 min, whereas times to 25% and 50% recovery were not significantly prolonged [6] . Magorian and colleagues nondepolarising relaxants has been related to the resistance of cirrhotic patients to them, a phenomenon first noted for found that time to 25% recovery of T 1 5T 0 was prolonged from 47 to 73 min, a difference which just failed to reach tubocurarine [18] ; as noted above, we found no evidence of resistance to rocuronium in cirrhosis. statistical significance, though they did not determine this time in three of their 10 cirrhotic patients; they did not A three compartment model fitted the present data much better than a two compartment model. Two previous studies present any pharmacodynamic data beyond that point [7] .
The most significant effect of cirrhosis on the pharmacowhich have used a population approach [7, 19] have found that a three compartment model produced a significantly kinetics of rocuronium in this study was the decrease in clearance compared with healthy patients. This finding is superior model fit to a two compartment model. Likewise, in a study of rocuronium in healthy patients, a consistent with work by Khuenl-Brady and colleagues in the cat, showing hepatic uptake and biliary excretion to be tri-exponential equation fitted the plasma concentration data best [10]. Khalil and colleagues, however, fitted a the predominant pathway for clearance of rocuronium [5] . They were able to recover 75% of an injected dose of bi-exponential equation to their plasma concentration data [6] . The ability accurately to define peripheral compartments, rocuronium in the liver and bile; only 8.7% appeared unchanged in the urine. Previous studies have failed to and the associated terminal elimination phase, depends upon the duration of sampling. Whilst some previous workers demonstrate a significant decrease in clearance of rocuronium in patients with hepatic disease, although the patients studied sampled only for 360 min following the rocuronium bolus [6, 7, 14] , we continued to sample up to 480 min, in order previously were if anything more severely diseased [6, 7] . The present values of clearance cannot be compared directly to define better the terminal elimination phase. It is of some clinical importance that we found onset time with those obtained by Magorian and others [7] , who did not normalise their results to take account of body to be similar in both groups, and indicates that rocuronium may be used safely to achieve a rapid onset of paralysis in weight. Our value for clearance in the cirrhotic group (2.66 ml kg −1 min −1 ) is similar to that reported by Khalil patients with liver disease; a similar finding was reported by Magorian and others [7] . In contrast Khalil and others and others (2.41 ml kg −1 min −1 ) [6] , who found a nonsignificant tendency to decreased clearance in cirrhosis. But reported a slower onset in cirrhosis (158 vs 108 s) [6] , and considered this to be caused by an increased initial volume our healthy patients had a considerably higher clearance of 3.7 ml min −1 kg −1 , which is similar to the values previously of distribution in cirrhotic patients. Our present finding that onset time is not increased in cirrhosis is consistent with the found in healthy patients of 4.0 ml min [14] . fact that we did not find V 1 to be significantly increased in the cirrhotic group. We found only small increases in both the central and total volumes of distribution, V 1 and V ss , which did not
We cannot explain the larger value of k eo in the cirrhotic group; it must reflect a more rapid equilibration between reach statistical significance. In contrast, Khalil found a significant increase in the central volume of distribution, the plasma and the site of action in the cirrhotic than in the of rocuronium in patients with cirrhosis. cirrhotic patients. This implies that the differences between
